|
Jun 20
|
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 28
|
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 28
|
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
|
Jan 11
|
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|
|
Jan 9
|
Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...
|
|
Dec 6
|
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
|
|
Dec 6
|
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
|
|
Dec 6
|
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Dec 1
|
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
|
Aug 10
|
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|
|
Aug 8
|
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|
|
Apr 27
|
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
|
|
Apr 24
|
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
|